Patents by Inventor Y. Lynn Wang

Y. Lynn Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BTK MUTATION AND IBRUTINIB RESISTANCE
    Publication number: 20220090208
    Abstract: Provided herein are mutations in Bruton's Tyrosine Kinase (BTK) that confer resistance to treatment with a BTK inhibitors, such as Ibrutinib, and compositions and methods for the treatment, diagnosis, and characterization of BTK-inhibitor-resistant cancers.
    Type: Application
    Filed: August 11, 2021
    Publication date: March 24, 2022
    Inventor: Y. Lynn Wang
  • BTK mutation and ibrutinib resistance
    Patent number: 11118233
    Abstract: Provided herein are mutations in Bruton's Tyrosine Kinase (BTK) that confer resistance to treatment with a BTK inhibitors, such as Ibrutinib, and compositions and methods for the treatment, diagnosis, and characterization of BTK-inhibitor-resistant cancers.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: September 14, 2021
    Assignee: The University of Chicago
    Inventor: Y. Lynn Wang
  • PERSONALIZED LEUKEMIA/LYMPHOMA THERAPEUTIC MODEL
    Publication number: 20210228646
    Abstract: The disclosure is directed to an ex vivo cell culture system and methods of using the cell culture system to identify potential therapeutic agents for the treatment of leukemia or lymphoma, such as chronic lymphocytic leukemia (CLL). The ex vivo culture system comprises (a) a first cell culture comprising bone marrow stromal cells (BMSC) which express one or more exogenous cell signaling molecules; (b) a second cell culture comprising leukemia or lymphoma cells isolated from a human; and optionally (c) one or more soluble cell signaling molecules.
    Type: Application
    Filed: April 30, 2019
    Publication date: July 29, 2021
    Inventors: Y. Lynn Wang, Pin Lu
  • BTK MUTATION AND IBRUTINIB RESISTANCE
    Publication number: 20190153543
    Abstract: Provided herein are mutations in Bruton's Tyrosine Kinase (BTK) that confer resistance to treatment with a BTK inhibitors, such as Ibrutinib, and compositions and methods for the treatment, diagnosis, and characterization of BTK-inhibitor-resistant cancers.
    Type: Application
    Filed: May 18, 2017
    Publication date: May 23, 2019
    Inventor: Y. Lynn Wang